Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Tectonic Therapeutic, Inc.

TECX ✗ NOT COMPLIANTFree checks used up today ☆ Track — members

NASDAQ · Healthcare · Biotechnology & Medical Research ·

USA Small Cap Analyst: BUY

Last Close

$19.78

▼ -3.51%

Market Cap $386.69M · Vol 47.45K

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$386.69M

Small Cap

Div Yield

N/A

EPS Growth

-25.77%

YoY

RSI (14)

31.24

Momentum

Beta

1.28

vs Market

52W High

$38.75

48.95% below

52W Low

$15.60

26.79% above

Volume

47.45K

Avg 70.42K

P/B

1.56

Price-to-book

ROE

N/A

Return on equity

Free Float

60.73%

Public shares

Shariah Compliance8 STANDARDS

✗ Tectonic Therapeutic, Inc. (TECX) stock is currently not Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does TECX pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-1.44%

-15.07%

-30.62%

-29.28%

YTD

-5.18%

+12.39%

+3.67%

-70.67%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-74,151,000.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	-35.23% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	1.56
P/FCF	N/A
EPS Growth	-25.77%
Outstanding Shares	19.55M

Technical Indicators

50-Day SMA	$26.01
200-Day SMA	$28.08
RSI (14)	31.24
Beta	1.28
52-Week High	$38.75
52-Week Low	$15.60

Volume Today	47.45K
Avg Daily Volume (30D)	70.42K
Relative Volume	0.67x
Volatility (10D)	41.43
Volatility (30D)	38.69
Free Float	60.73%

Analyst Consensus

BUY

Current Price $19.78

Mean Target $76.63

52W Low$15.60 52W High$38.75

Current

Target

$15.60 $38.75

Current Analyst target

+287.39% upside potential · 8 analysts

Identifiers

ExchangeNASDAQ

FIGIBBG00DJ4T7F9

ISINUS8789721086

CountryUSA

Sub-IndustryBio Therapeutic Drugs

Earnings DateNov 4, 2026

TypeStocks

Instrument TypeADR American Depositary Receipt

Similar Halal Stocks

2359.HK WuXi AppTec Co., Ltd. -2.98% ARGX.BR argenx SE +0.35% ARGX argenx SE -0.55% GMAB.CO Genmab A/S +3.27% GMAB Genmab A/S +1.01%

Company Profile

Tectonic Therapeutic, Inc. is a clinical-stage biotechnology company. The Company is focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs). Its technology platform called GEODe (GPCRs Engineered for Optimal Discovery), is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery and harness the human body to modify the course of disease. Its product candidates are TX45, a Fc-relaxin fusion molecule that activates the RXFP1 receptor, the GPCR target of the hormone relaxin. Its second development candidate, TX2100, is a VHH-Fc fusion antagonist antibody that binds to the APJ receptor (APLNR), also known as the apelin receptor. Its APJ is a differentiated approach for the treatment of hereditary hemorrhagic telangiectasia (HHT) and is a selective anti-angiogenic target that is primarily expressed in endothelial cells.